Mylan's complex product pipeline doesn't diminish broader challenges in the generic drug industry.
Mylan hit a rough patch during the second quarter thanks to competitive pressure on existing products, a lack of major product launches, and regulatory and restructuring issues. As a result, management significantly lowered its year-end outlook, including a revenue and adjusted EPS estimate reduction to $11.75 billion and $4.73 at the midpoint, respectively, which are both below our estimates and imply nearly flat growth for the year. We plan to lower our fair value after adjusting our model. Wh...
Morningstar, Inc. is a leading provider of independent investment research in North America, Europe, Australia, and Asia. The company offer an extensive line of products and services for individual investors, financial advisors, asset managers, and retirement plan providers and sponsors.
Morningstar provides data on approximately 530,000 investment offerings, including stocks, mutual funds, and similar vehicles, along with real-time global market data on more than 18 million equities, indexes, futures, options, commodities, and precious metals, in addition to foreign exchange and Treasury markets. Morningstar also offers investment management services through its investment advisory subsidiaries and had approximately $185 billion in assets under advisement and management as of June 30, 2016.
We have operations in 27 countries.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.